Last reviewed · How we verify
US-guided tenotomy with PRP
US-guided tenotomy with PRP is a Small molecule drug developed by Jose Ignacio Martin. It is currently in Phase 3 development for Tendinopathy, including Achilles tendonitis and rotator cuff tendinosis. Also known as: pure-PRP (without leukocytes).
US-guided tenotomy with PRP is a minimally invasive procedure that uses ultrasound guidance to release tension in tendons and ligaments, with the addition of platelet-rich plasma (PRP) to promote healing.
US-guided tenotomy with PRP is a treatment that has been studied for chronic epicondylitis, a condition affecting the elbow. This treatment involves using ultrasound guidance to perform a tenotomy, a procedure to cut a tendon, and injecting platelet-rich plasma (PRP) into the affected area.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | US-guided tenotomy with PRP |
|---|---|
| Also known as | pure-PRP (without leukocytes) |
| Sponsor | Jose Ignacio Martin |
| Modality | Small molecule |
| Therapeutic area | Orthopedics |
| Phase | Phase 3 |
Mechanism of action
The procedure involves inserting a small needle under ultrasound guidance to release scar tissue and adhesions in tendons and ligaments. The addition of PRP, which is derived from the patient's own blood, is thought to enhance the healing process by promoting the growth of new tissue and reducing inflammation.
Approved indications
- Tendinopathy, including Achilles tendonitis and rotator cuff tendinosis
Common side effects
- Pain, swelling, and bruising at the injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US-guided tenotomy with PRP CI brief — competitive landscape report
- US-guided tenotomy with PRP updates RSS · CI watch RSS
- Jose Ignacio Martin portfolio CI
Frequently asked questions about US-guided tenotomy with PRP
What is US-guided tenotomy with PRP?
How does US-guided tenotomy with PRP work?
What is US-guided tenotomy with PRP used for?
Who makes US-guided tenotomy with PRP?
Is US-guided tenotomy with PRP also known as anything else?
What development phase is US-guided tenotomy with PRP in?
What are the side effects of US-guided tenotomy with PRP?
Related
- Manufacturer: Jose Ignacio Martin — full pipeline
- Therapeutic area: All drugs in Orthopedics
- Indication: Drugs for Tendinopathy, including Achilles tendonitis and rotator cuff tendinosis
- Also known as: pure-PRP (without leukocytes)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing